SRL
TVTX icon

Scientech Research LLC’s Travere Therapeutics TVTX Stock Holding History

Scientech Research LLC’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,091
Closed -$90.6K – 583
2023
Q4 		$90.6K Buy
+10,091
New +$73.5K 0.09% 273

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Scientech Research LLC's TVTX Position: Q1 2024 in Review

Scientech Research LLC sold out of Travere Therapeutics (TVTX) in Q1 2024, closing a stake of 10,091 shares — an estimated $90.6K sold.

Scientech Research LLC first reported a position in TVTX in Q4 2023 and held it in 1 quarter. The position peaked at $90.6K in Q4 2023. 175 funds tracked by Wall St. Rank hold TVTX as of Q1 2024.

  • Scientech Research LLC reported no remaining Travere Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Scientech Research LLC sold 10,091 Travere Therapeutics shares in Q1 2024, an estimated $90.6K.
  • Scientech Research LLC first reported a position in Travere Therapeutics in Q4 2023 and held it in 1 quarter.
  • Scientech Research LLC's Travere Therapeutics position peaked at $90.6K in Q4 2023.
  • 175 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2024.

Based on Scientech Research LLC's 13F filing for Q1 2024, filed 15 May 2024.